KC-6806

293T-PLAUR-Low Cell Line

×
67885
Home » 293T-PLAUR-Low Cell Line

Background of 293T-PLAUR-Low Cell Line

PLAUR (Plasminogen Activator, Urokinase Receptor) , also known as uPAR (urokinase plasminogen activator receptor) or CD87, is a glycosylphosphatidylinositol (GPI)-anchored membrane protein encoded on chromosome 19q13.31. It binds urokinase plasminogen activator (uPA) and promotes plasminogen activation, pericellular proteolysis, cell migration, and invasion. PLAUR is expressed in various tissues including monocytes, neutrophils, and vascular endothelial cells. Overexpression of PLAUR is observed in multiple cancers, including breast, colorectal, lung, and prostate cancers, correlating with poor prognosis, tumor invasion, and metastasis. PLAUR has emerged as a therapeutic target, with strategies including uPAR-targeting antibodies, small molecule inhibitors, and immunotoxins under preclinical and early clinical investigation.

Specifications

Catalog NumberKC-6806
Cell Line Name293T-PLAUR-Low Cell Line
NCBI/UniProt Accession NumberNM_002659.4
Clone Number1#
Host Cell Line293T Cell Line
DescriptionStable 293T cell line expressing exogenous human PLAUR gene at low level.
QuantityOne vial of frozen cells (≥2×106 cells)
StabilityStable in culture over a minimum of 10 passages
ApplicationDrug screening and biological assays
Freezing Medium70% DMEM + 20% FBS + 10% DMSO
Propagation MediumDMEM + 10% FBS + 1μg/mL Puromycin
Selection MarkerPuromycin
MorphologyEpithelial
SubcultureSplit saturated culture 1:4-1:8 every 2-3 days
Incubation37 °C with 5% CO2
StorageLiquid nitrogen immediately upon receiving
Doubling TimeApproximately 30 hours
Mycoplasma StatusNegative
In Vivo ValidationYES

Cell Line Generation

The 293T-PLAUR-Low cell line was generated using a plasmid vector expressing the human PLAUR sequence, followed by selection for low-expression clones.

Characterization

Figure 1: Characterization of human PLAUR overexpression in the 293T-PLAUR-Low stable clone using FACS.

Figure 2: Characterization of human PLAUR overexpression in the 293T-PLAUR-Low stable clone using PCR sequencing.

Cell Resuscitation

  1. Pre-warm complete culture medium (basal medium and 10% FBS) in a 37°C water bath.
  2. Rapidly thaw the cryovial in a 37°C water bath for 1-2 minutes with gentle agitation.
  3. Transfer the vial to a biosafety cabinet, and disinfect the exterior with 70% ethanol.
  4. Aseptically transfer the cell suspension dropwise into a sterile centrifuge tube containing 9.0 mL of pre-warmed complete medium.
  5. Centrifuge at approximately 125 × g for 5–7 minutes at room temperature, carefully aspirate the supernatant without disturbing the cell pellet.
  6. Gently resuspend the pellet in an appropriate volume of complete medium and transfer the suspension into a T25 flask.
  7. Incubate the flask in a 37°C in a humidified 5% CO2 incubator.
  8. Assess cell viability and morphology after 24 hours. If cells appear healthy, replace the medium with fresh medium supplemented with the appropriate selective antibiotic.
  9. Subculture the cells at a ratio of 1:4-1:8 every 2-3 days upon reaching 80%–90% confluency.

Cell Freezing

  1. Prepare the freezing medium (70% basal medium, 20% FBS and 10% DMSO) freshly before use.
  2. Pre-chill the freezing medium on ice and label the cryovials accordingly.
  3. Transfer the cell suspension to a sterile conical tube and perform a cell count to determine total viability and density.
  4. Centrifuge the cells at 250×g for 5 minutes at room temperature; carefully aspirate the supernatant.
  5. Gently resuspend the cell pellet in chilled freezing medium, ensuring a minimum cell density of 3×106 cells/mL.
  6. Aliquot 1 mL of the cell suspension into each pre-labeled cryovial.
  7. Place the cryovials into a CoolCell® container and store at -80°C overnight for controlled-rate cooling.
  8. Transfer the cryovials to the liquid nitrogen for long-term storage the following day.

References

1. Penkov, Dmitry et al. “Endothelial-specific Enhancer as a Cis Element of PLAUR Regulation by TNF-alpha, IL-1beta, and VEGF.” Current pharmaceutical design vol. 30,21 (2024): 1630-1640. doi:10.2174/0113816128296376240424072322
2. Hindy, George et al. “Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis.” The Journal of clinical investigation vol. 132,24 e158788. 15 Dec. 2022, doi:10.1172/JCI158788

Use License Agreement

Research Use Only.
Not for use in diagnostic procedures or therapeutic applications.
Redistribution of the cell line or its derivatives is prohibited without prior written permission from Kyinno Biotechnology.